🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 47 of 55

  1. Taxotere

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  2. Tazemetostat

    Eisai Co.,

    Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    Tour Hekla

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  4. Tecentriq 1 200 mg concentrate for solution for infusion

    The George Institute

    Locally advanced cervical cancer

    phase 2 small molecule active

    1 trial

  5. Tecentriq 1 200 mg concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    Limited disease small-cell lung cancer

    phase 2 small molecule active

    1 trial

  6. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Muscle-invasive bladder cancer

    phase 2 small molecule active

    1 trial

  7. Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    (Diffuse) Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  8. Tecentriq 1 200 mg concentrate for solution for infusion, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.

    phase 2 small molecule active

    1 trial

  9. Tecentriq 1 200 mg concentrate for solution for infusion, EIK1001 solution for injection 1.0 mg/mL free base equivalent

    The George Institute

    Adult participants with metastatic (advanced) solid tumors.

    phase 2 small molecule active

    1 trial

  10. Tecentriq 1 200 mg concentrate for solution for infusion, OXALIPLATINE HOSPIRA 5 mg/ml, solution à diluer pour perfusion, Avastin 25 mg/ml concentrate for solution for infusion., CAPECITABINE VIATRIS 500 mg, comprimé pelliculé

    CERO THERAPEUTICS HOLDINGS, INC.

    microsatellite stable (MSS) colorectal cancer with liver-dominant metastasis

    phase 2 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion, Pulmocis 2 mg trousse pour préparation radiopharmaceutique, Avastin 25 mg/ml concentrate for solution for infusion.

    The George Institute

    Non resectable Hepatocellular carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  12. Tecentriq 1 200 mg concentrate for solution for infusion, Tiragolumab

    Disc Medicine

    Squamous cell carcinoma of the anal canal

    phase 2 small molecule active

    1 trial

  13. Tecentriq 1,200 mg concentrate for solution for infusion, EXL01, IMFINZI 50 mg/mL concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq 840 mg concentrate for solution for infusion, IMJUDO 20 mg/ml concentrate for solution for infusion., Avastin 25 mg/ml concentrate for solution for infusion.

    Ningbo Cancer Hospital

    Hepatocellular carcinoma

    phase 2 small molecule active

    1 trial

  14. Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  15. Tecentriq 840 mg concentrate for solution for infusion, Tiragolumab

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  16. Tegafur Gimeracil Oteracil Potassium Capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 2 small molecule active

    1 trial

  17. Telehealth Intervention

    United Therapeutics Europe Ltd

    Colorectal Cancer

    phase 2 other active

    1 trial

  18. Telisotuzumab Vedotin

    AbbVie Deutschland GmbH & Co. KG

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Telisotuzumab adizutecan

    AbbVie Deutschland GmbH & Co. KG

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  20. Temsirolimus

    PUMA BIOTECHNOLOGY, INC.

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  21. Teniposide administration

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-stage Small Cell Lung Cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  22. Tepotinib

    Serono Europe Limited

    Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification

    phase 2 small molecule active

    1 trial

  23. Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  24. Testosterone Enanthate 100 MG/ML Injectable Solution

    Hospital Authority, Hong Kong

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  25. Testosterone cypionate

    United Therapeutics Europe Ltd

    Castration Resistant Metastatic Prostate Cancer

    phase 2 small molecule completed

    1 trial

  26. Teverelix TFA

    Nordic Bioscience A/S

    Advanced prostate cancer

    phase 2 small molecule active

    1 trial

  27. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  28. Tevimbra 100 mg concentrate for solution for infusion, Carboplatino Hikma 10 mg/ml soluzione per infusione, Cisplatino Hikma 1mg/ml concentrato per soluzione per infusione, Paclitaxel Accord Healthcare Italia 6 mg/ml, concentrato per soluzione per infusione, Pemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  29. Thalidomide and methotrexate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-LGL Leukemia

    phase 2 small molecule active

    1 trial

  30. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  31. Timolol Micro Labs 5 mg/ml Augentropfen, Losung, Zink Verla® 10 mg, Filmtabletten, Doxy-M-ratiopharm 100 mg tabletės, Protopic 0.1% ointment, ClobeGalen 500 Mikrogramm/g Shampoo, JNJ-73841937, Dociton® 10 mg Filmtabletten, Doxy-M-ratiopharm® 100 mg Tabletten, JNJ-61186372, MINOCIN 50 mg capsule rigide, Minocyclin-ratiopharm® 100 mg Hartkapseln, Protopic 0.1% ointment, Timolol 0,5 % AT - 1 A Pharma, 5 mg/ml Augentropfen, Lösung, Doxyderma 50 mg, Opzelura 15 mg/g cream, JNJ-61186372, Chlorhexidine, Dalacin 10

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. Tipifarnib

    Kura Oncology

    Thyroid Cancer

    phase 2 small molecule completed

    1 trial

  33. Tipifarnib

    Kura Oncology

    Relapsed or Refractory Peripheral T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  34. Tipifarnib

    Kura Oncology

    Leukemia, Myelomonocytic, Chronic

    phase 2 small molecule completed

    1 trial

  35. Tiragolumab

    Hoffmann-La Roche

    Cervical Cancer

    phase 2 small molecule completed

    1 trial

  36. Tiragolumab placebo, Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

  37. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion

    Disc Medicine

    HNSCC, metastatic deficient mismatch repair (dMMR)/MSI-high (MSI-H) tumors, irresectable or metastatic melanoma, locally advanced or metastatic solid tumor

    phase 2 small molecule active

    1 trial

  38. Tiragolumab, Tecentriq 1 200 mg concentrate for solution for infusion, RO7247669

    Hoffmann-La Roche

    Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

    phase 2 small molecule active

    1 trial

  39. Tislelizumab

    The First People's Hospital of Lianyungang

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  40. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 2 small molecule active

    1 trial

  41. Tislelizumab

    Hospital Authority, Hong Kong

    Pancreatic Neoplasms

    phase 2 small molecule active

    1 trial

  42. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  43. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Gastroesophageal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  44. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Colorectal Cancer

    phase 2 small molecule completed

    1 trial

  45. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thyroid Cancer

    phase 2 small molecule active

    1 trial

  46. Tislelizumab

    BEONE MEDICINES AUS PTY LTD

    Advanced Unresectable Gastric Adenocarcinoma

    phase 2 small molecule active

    1 trial

  47. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    RECTAL NEOPLASMS

    phase 2 small molecule active

    1 trial

  48. Tislelizumab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.